-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
Decanoyl-RVKR-CMK-TFA
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/2098497-25-5.gif)
| Category | Human immunodeficiency Virus (HIV) |
| CAS | 2098497-25-5 |
| Description | Decanoyl-RVKR-CMK (DecRVKRcmk) TFA inhibits over-expressed gp160 processing and HIV-1 replication. |
Product Information
| Synonyms | Decanoyl-RVKR-CMK (TFA)|HY-107760A |
| Molecular Weight | 858.43 |
| Molecular Formula | C36H67ClF3N11O7 |
| Purity | 96.40% |
| Solubility | In Vitro: H2O : 4 mg/mL(4.66 mM;Need ultrasonic) |
| Appearance | White to off-white (Solid) |
| Storage | Sealed storage, away from moisture Powder -80°C 2 years -20°C 1 years * In solvent -80°C 6 months -20°C 1 month (sealed storage, away from moisture and light) |
| In Vitro | Decanoyl-RVKR-CMK (DecRVKRcmk) TFA inhibits HIV-2ROD replication by blocking envelope glycoprotein precursor processing in the Jurkat lymphocyte cell. Decanoyl-RVKR-CMK (DecRVKRcmk) TFA blocks regulated secretion of VGF. Result: Peptide at 35 µM significantly inhibited ex vivo HIV-1 and HIV-2 replications (70-80% inhibition). |
| Target | HIV |
